• Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

  • 2025/02/13
  • 再生時間： 1 時間 59 分
  • ポッドキャスト

Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics:

    • Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry
      • Introduction (0:00)
      • Faculty Presentation (3:08)
      • IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43)
      • Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15)
      • Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34)
    • Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn
      • Faculty Presentation (31:18)
      • EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15)
      • Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29)
      • Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05)
    • Current First-Line Therapy for Advanced HCC — Dr He
      • Faculty Presentation (1:00:39)
      • Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00)
      • Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22)
      • Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03)
    • Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein
      • Faculty Presentation (1:29:42)
      • Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59)
      • Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27)
      • Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20)

    CME information and select publications
    続きを読む 一部表示

あらすじ・解説

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Richard S Finn, Dr Aiwu Ruth He and Dr Stacey Stein, moderated by Dr Stephen “Fred” Divers, including the following topics:

  • Adjuvant Systemic Therapy for Early-Stage Hepatocellular Carcinoma (HCC) — Dr El-Khoueiry
    • Introduction (0:00)
    • Faculty Presentation (3:08)
    • IMbrave050: Adjuvant systemic treatment for high-risk resected HCC — Robin K (Katie) Kelley, MD and Thomas A Abrams, MD (13:43)
    • Neoadjuvant systemic therapy for patients with borderline resectable HCC — Dr Abrams (20:15)
    • Case: A man in his early 70s with locally advanced HCC and tumor thrombus that extends into the right atrium — Ghassan Abou-Alfa, MD, MBA (24:34)
  • Recent Developments in the Management of Intermediate-Stage HCC — Dr Finn
    • Faculty Presentation (31:18)
    • EMERALD-1 and LEAP-012 trials of TACE with immunotherapy — Drs Abrams and Kelley (42:15)
    • Systemic treatment for patients with Child-Pugh B cirrhosis and HCC — Dr Kelley (48:29)
    • Use of immunotherapy for patients with autoimmune disorders: A man in his early 30s with active colitis and metastatic HCC receives first-line lenvatinib — Drs Abrams and Abou-Alfa (53:05)
  • Current First-Line Therapy for Advanced HCC — Dr He
    • Faculty Presentation (1:00:39)
    • Selection of first-line treatment regimen for advanced HCC — Drs Abrams, Kelley and Abou-Alfa (1:12:00)
    • Role of single-agent immunotherapy in the treatment of advanced HCC — Dr Kelley (1:18:22)
    • Management of HCC in patients with discordant tumor markers or mixed tumor histology — Dr Abrams (1:23:03)
  • Promising Investigational Front-Line Strategies for Advanced HCC; Selection and Sequencing of Therapy for Relapsed/Refractory HCC — Dr Stein
    • Faculty Presentation (1:29:42)
    • Choice of tyrosine kinase inhibitor as second-line systemic treatment for HCC; prevention, monitoring and mitigation of lenvatinib-associated side effects — Dr Kelley (1:42:59)
    • Case: A man in his early 70s with metastatic HCC that has rapidly progressed on atezolizumab/bevacizumab — Dr Abou-Alfa (1:49:27)
    • Supportive care measures to manage ascites in patients with HCC — Dr Abrams (1:55:20)

CME information and select publications
続きを読む 一部表示
activate_buybox_copy_target_t1

Hepatocellular Carcinoma — Proceedings From a Session Held in Conjunction with the 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI)に寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。